Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51) View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2001-03

AUTHORS

P. Clarke, A. Gray, A. Adler, R. Stevens, M. Raikou, C. Cull, I. Stratton, R. Holman, on behalf of the UKPDS Group

ABSTRACT

Aims/hypothesis. To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. Methods. Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight ( > 120 % ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. Results. Intensive blood-glucose control with metformin produced a net saving of £ 258 per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6 %). Conclusions/interpretation. As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike. [Diabetologia (2001) 44: 298–304] More... »

PAGES

298-304

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s001250051617

DOI

http://dx.doi.org/10.1007/s001250051617

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001128875

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/11317659


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose Self-Monitoring", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Body Mass Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Costs and Cost Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diet, Diabetic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "England", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Insulin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Metformin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Northern Ireland", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Obesity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Education as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Scotland", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United Kingdom", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clarke", 
        "givenName": "P.", 
        "id": "sg:person.0734456474.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "A.", 
        "id": "sg:person.01307325071.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Adler", 
        "givenName": "A.", 
        "id": "sg:person.01327503373.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327503373.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stevens", 
        "givenName": "R.", 
        "id": "sg:person.01052527755.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Economics, City University, London, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.28577.3f", 
          "name": [
            "Department of Economics, City University, London, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raikou", 
        "givenName": "M.", 
        "id": "sg:person.0720431761.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720431761.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cull", 
        "givenName": "C.", 
        "id": "sg:person.0637007241.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637007241.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stratton", 
        "givenName": "I.", 
        "id": "sg:person.01201354332.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201354332.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Holman", 
        "givenName": "R.", 
        "id": "sg:person.01017043005.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "on behalf of the UKPDS Group", 
        "type": "Person"
      }
    ], 
    "datePublished": "2001-03", 
    "datePublishedReg": "2001-03-01", 
    "description": "Aims/hypothesis. To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. Methods. Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight ( > 120 % ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. Results. Intensive blood-glucose control with metformin produced a net saving of \u00a3 258 per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6 %). Conclusions/interpretation. As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike. [Diabetologia (2001) 44: 298\u2013304]", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s001250051617", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1001482", 
        "issn": [
          "0012-186X", 
          "1432-0428"
        ], 
        "name": "Diabetologia", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "intensive blood-glucose control", 
      "blood-glucose control", 
      "overweight patients", 
      "cost-effectiveness analysis", 
      "type II diabetes", 
      "conventional therapy", 
      "life expectancy", 
      "first line pharmacological therapy", 
      "UK Prospective Diabetes Study", 
      "hospital-based clinics", 
      "type II diabetic patients", 
      "Prospective Diabetes Study", 
      "patient level data", 
      "health care resources", 
      "diabetic patients", 
      "pharmacological therapy", 
      "Diabetes Study", 
      "complication costs", 
      "metformin", 
      "patients", 
      "care resources", 
      "trial effects", 
      "therapy", 
      "trial period", 
      "care managers", 
      "diabetes", 
      "type II", 
      "health care managers", 
      "net savings", 
      "diet", 
      "expectancy", 
      "mellitus", 
      "clinic", 
      "control", 
      "clinicians", 
      "trials", 
      "subjects", 
      "United Kingdom", 
      "years", 
      "period", 
      "Northern Ireland", 
      "study", 
      "analysis", 
      "effect", 
      "use", 
      "data", 
      "level data", 
      "effectiveness", 
      "England", 
      "Scotland", 
      "Kingdom", 
      "part", 
      "Ireland", 
      "cost", 
      "control policies", 
      "conventional policy", 
      "policy", 
      "terms", 
      "savings", 
      "resources", 
      "managers", 
      "economic efficiency", 
      "efficiency", 
      "II diabetes", 
      "intensive blood-glucose control policy", 
      "blood-glucose control policy", 
      "lower complication costs", 
      "line pharmacological therapy", 
      "overweight Type II diabetic patients", 
      "II diabetic patients"
    ], 
    "name": "Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51)", 
    "pagination": "298-304", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001128875"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s001250051617"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "11317659"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s001250051617", 
      "https://app.dimensions.ai/details/publication/pub.1001128875"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_335.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s001250051617"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s001250051617'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      21 PREDICATES      121 URIs      113 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s001250051617 schema:about N1f587d68749540b8ba86b916348b3c42
2 N252ead09d703431fbd0e7b998d2ba823
3 N3b46afae1eca4b6caa2a151c9fc2a8aa
4 N400aaf7e3b2848cd96eaa46092ba6df5
5 N57652090fa714df18d7ea60cc6e246b4
6 N5ca281b8c1304782ba73ae2fe65b9122
7 N6120f16475c347c89dfa9516c03c608d
8 N6eacf7afe0464026b1c780632896f5e8
9 N7842a87973434b4896c85af0ff460dca
10 N7b5d9805223443508d7ed51e6804ff1b
11 N7f2e75718bbb45509177d5f092862eca
12 N91fa72750a73437088fee12a5c64dfff
13 N9ed2dc3ab8d64a5da998434a5b6ff83e
14 Na2779d7178bb4d6cb8c0a9b2b4a2da7e
15 Na6a031b19d9448c7851bbcae77f7d89c
16 Nca6554ca99b843ec89212547e58ca699
17 Nd7605dbf5c6d4e12b0328e28a4f0fa69
18 Ndc9255cb7da647b8a5c070f56eb397c0
19 Nde069ce055ff488a9c25ae5452da0ac7
20 Ne84c942e419f4088b00700b09d550e5f
21 Ne89d174b56f746b38eff437d0bfafdd1
22 Ne9e6e73748434e8dac241adc230715d0
23 Neac4c763cb124921a8fcd7adbfdfe3b7
24 Nfa504b69c1cc47eaaad49c31d97a53aa
25 anzsrc-for:11
26 anzsrc-for:1103
27 schema:author N713eacf4630d46c2b29cd62cd1ed293c
28 schema:datePublished 2001-03
29 schema:datePublishedReg 2001-03-01
30 schema:description Aims/hypothesis. To estimate the economic efficiency of intensive blood-glucose control with metformin compared with conventional therapy primarily with diet in overweight patients with Type II (non-insulin-dependent) diabetes mellitus. Methods. Cost-effectiveness analysis based on patient level data from a randomised clinical controlled trial involving 753 overweight ( > 120 % ideal body weight) patients with newly diagnosed Type II diabetes conducted in 15 hospital-based clinics in England, Scotland and Northern Ireland as part of the UK Prospective Diabetes Study. Subjects were allocated at random to an intensive blood-glucose control policy with metformin (n = 342) or a conventional policy primarily with diet (n = 411). The analysis was based on the cost of health care resources associated with metformin and conventional therapy and the estimated effectiveness in terms of life expectancy gained from within-trial effects. Results. Intensive blood-glucose control with metformin produced a net saving of £ 258 per patient (1997 United Kingdom prices) over the trial period (median duration of 10.7 years) due to lower complication costs, and increased life expectancy by 0.4 years (costs and benefits discounted at 6 %). Conclusions/interpretation. As metformin is both cost-saving in the United Kingdom and extends life expectancy when used as first line pharmacological therapy in overweight Type II diabetic patients, its use should be attractive to clinicians and health care managers alike. [Diabetologia (2001) 44: 298–304]
31 schema:genre article
32 schema:inLanguage en
33 schema:isAccessibleForFree true
34 schema:isPartOf Na63d47623e784d798d6d7a1c71f3f338
35 Nc0511653844c41b3b68fc100ce92bb1d
36 sg:journal.1001482
37 schema:keywords Diabetes Study
38 England
39 II diabetes
40 II diabetic patients
41 Ireland
42 Kingdom
43 Northern Ireland
44 Prospective Diabetes Study
45 Scotland
46 UK Prospective Diabetes Study
47 United Kingdom
48 analysis
49 blood-glucose control
50 blood-glucose control policy
51 care managers
52 care resources
53 clinic
54 clinicians
55 complication costs
56 control
57 control policies
58 conventional policy
59 conventional therapy
60 cost
61 cost-effectiveness analysis
62 data
63 diabetes
64 diabetic patients
65 diet
66 economic efficiency
67 effect
68 effectiveness
69 efficiency
70 expectancy
71 first line pharmacological therapy
72 health care managers
73 health care resources
74 hospital-based clinics
75 intensive blood-glucose control
76 intensive blood-glucose control policy
77 level data
78 life expectancy
79 line pharmacological therapy
80 lower complication costs
81 managers
82 mellitus
83 metformin
84 net savings
85 overweight Type II diabetic patients
86 overweight patients
87 part
88 patient level data
89 patients
90 period
91 pharmacological therapy
92 policy
93 resources
94 savings
95 study
96 subjects
97 terms
98 therapy
99 trial effects
100 trial period
101 trials
102 type II
103 type II diabetes
104 type II diabetic patients
105 use
106 years
107 schema:name Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No. 51)
108 schema:pagination 298-304
109 schema:productId N0755ad86691b42688892508923fe1b42
110 N17ba95f1f3de4e2e99cb0cde8ba15738
111 Naed9e331a8884809ae1d8c0ff7b22b05
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001128875
113 https://doi.org/10.1007/s001250051617
114 schema:sdDatePublished 2021-11-01T18:04
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher N40da015b8a7b4b7799713d10fb5addb0
117 schema:url https://doi.org/10.1007/s001250051617
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N02545675dc6c4ca59ebb44b5ea978dfa rdf:first sg:person.01327503373.58
122 rdf:rest N65af7cfba9af4c688b0f32f5cf21e958
123 N0755ad86691b42688892508923fe1b42 schema:name doi
124 schema:value 10.1007/s001250051617
125 rdf:type schema:PropertyValue
126 N17ba95f1f3de4e2e99cb0cde8ba15738 schema:name dimensions_id
127 schema:value pub.1001128875
128 rdf:type schema:PropertyValue
129 N1ec2bef171ae47e3bf255888b87bc96f rdf:first N6faced4991ce4e7c9cc51d914669841f
130 rdf:rest rdf:nil
131 N1f587d68749540b8ba86b916348b3c42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Aged
133 rdf:type schema:DefinedTerm
134 N252ead09d703431fbd0e7b998d2ba823 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Diet, Diabetic
136 rdf:type schema:DefinedTerm
137 N29a33ba1c82c4a67a4247544a5d8cec4 rdf:first sg:person.0720431761.48
138 rdf:rest Nd0b5a9921f50458c9d200be74cd13d9e
139 N3b46afae1eca4b6caa2a151c9fc2a8aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Diabetes Mellitus, Type 2
141 rdf:type schema:DefinedTerm
142 N400aaf7e3b2848cd96eaa46092ba6df5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Obesity
144 rdf:type schema:DefinedTerm
145 N40da015b8a7b4b7799713d10fb5addb0 schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 N49ea612ac6174108a0409ab3afc597e1 rdf:first sg:person.01017043005.08
148 rdf:rest N1ec2bef171ae47e3bf255888b87bc96f
149 N57652090fa714df18d7ea60cc6e246b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Adult
151 rdf:type schema:DefinedTerm
152 N58f18ed2bba346c99bea2f662526989f rdf:first sg:person.01307325071.02
153 rdf:rest N02545675dc6c4ca59ebb44b5ea978dfa
154 N5ca281b8c1304782ba73ae2fe65b9122 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hypoglycemic Agents
156 rdf:type schema:DefinedTerm
157 N6120f16475c347c89dfa9516c03c608d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Middle Aged
159 rdf:type schema:DefinedTerm
160 N65af7cfba9af4c688b0f32f5cf21e958 rdf:first sg:person.01052527755.23
161 rdf:rest N29a33ba1c82c4a67a4247544a5d8cec4
162 N6eacf7afe0464026b1c780632896f5e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Body Mass Index
164 rdf:type schema:DefinedTerm
165 N6faced4991ce4e7c9cc51d914669841f schema:familyName on behalf of the UKPDS Group
166 rdf:type schema:Person
167 N713eacf4630d46c2b29cd62cd1ed293c rdf:first sg:person.0734456474.38
168 rdf:rest N58f18ed2bba346c99bea2f662526989f
169 N7842a87973434b4896c85af0ff460dca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Antihypertensive Agents
171 rdf:type schema:DefinedTerm
172 N7b5d9805223443508d7ed51e6804ff1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Diabetes Mellitus
174 rdf:type schema:DefinedTerm
175 N7f2e75718bbb45509177d5f092862eca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Blood Glucose
177 rdf:type schema:DefinedTerm
178 N8aa88629d7c749c08ef94be6b697771a rdf:first sg:person.01201354332.66
179 rdf:rest N49ea612ac6174108a0409ab3afc597e1
180 N91fa72750a73437088fee12a5c64dfff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Costs and Cost Analysis
182 rdf:type schema:DefinedTerm
183 N9ed2dc3ab8d64a5da998434a5b6ff83e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Hypertension
185 rdf:type schema:DefinedTerm
186 Na2779d7178bb4d6cb8c0a9b2b4a2da7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name United Kingdom
188 rdf:type schema:DefinedTerm
189 Na63d47623e784d798d6d7a1c71f3f338 schema:issueNumber 3
190 rdf:type schema:PublicationIssue
191 Na6a031b19d9448c7851bbcae77f7d89c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name England
193 rdf:type schema:DefinedTerm
194 Naed9e331a8884809ae1d8c0ff7b22b05 schema:name pubmed_id
195 schema:value 11317659
196 rdf:type schema:PropertyValue
197 Nc0511653844c41b3b68fc100ce92bb1d schema:volumeNumber 44
198 rdf:type schema:PublicationVolume
199 Nca6554ca99b843ec89212547e58ca699 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Humans
201 rdf:type schema:DefinedTerm
202 Nd0b5a9921f50458c9d200be74cd13d9e rdf:first sg:person.0637007241.52
203 rdf:rest N8aa88629d7c749c08ef94be6b697771a
204 Nd7605dbf5c6d4e12b0328e28a4f0fa69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Metformin
206 rdf:type schema:DefinedTerm
207 Ndc9255cb7da647b8a5c070f56eb397c0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Cost-Benefit Analysis
209 rdf:type schema:DefinedTerm
210 Nde069ce055ff488a9c25ae5452da0ac7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Patient Education as Topic
212 rdf:type schema:DefinedTerm
213 Ne84c942e419f4088b00700b09d550e5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Blood Glucose Self-Monitoring
215 rdf:type schema:DefinedTerm
216 Ne89d174b56f746b38eff437d0bfafdd1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Scotland
218 rdf:type schema:DefinedTerm
219 Ne9e6e73748434e8dac241adc230715d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Northern Ireland
221 rdf:type schema:DefinedTerm
222 Neac4c763cb124921a8fcd7adbfdfe3b7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Insulin
224 rdf:type schema:DefinedTerm
225 Nfa504b69c1cc47eaaad49c31d97a53aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
226 schema:name Cross-Sectional Studies
227 rdf:type schema:DefinedTerm
228 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
229 schema:name Medical and Health Sciences
230 rdf:type schema:DefinedTerm
231 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
232 schema:name Clinical Sciences
233 rdf:type schema:DefinedTerm
234 sg:journal.1001482 schema:issn 0012-186X
235 1432-0428
236 schema:name Diabetologia
237 schema:publisher Springer Nature
238 rdf:type schema:Periodical
239 sg:person.01017043005.08 schema:affiliation grid-institutes:grid.4991.5
240 schema:familyName Holman
241 schema:givenName R.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017043005.08
243 rdf:type schema:Person
244 sg:person.01052527755.23 schema:affiliation grid-institutes:grid.4991.5
245 schema:familyName Stevens
246 schema:givenName R.
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052527755.23
248 rdf:type schema:Person
249 sg:person.01201354332.66 schema:affiliation grid-institutes:grid.4991.5
250 schema:familyName Stratton
251 schema:givenName I.
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01201354332.66
253 rdf:type schema:Person
254 sg:person.01307325071.02 schema:affiliation grid-institutes:grid.4991.5
255 schema:familyName Gray
256 schema:givenName A.
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307325071.02
258 rdf:type schema:Person
259 sg:person.01327503373.58 schema:affiliation grid-institutes:grid.4991.5
260 schema:familyName Adler
261 schema:givenName A.
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01327503373.58
263 rdf:type schema:Person
264 sg:person.0637007241.52 schema:affiliation grid-institutes:grid.4991.5
265 schema:familyName Cull
266 schema:givenName C.
267 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637007241.52
268 rdf:type schema:Person
269 sg:person.0720431761.48 schema:affiliation grid-institutes:grid.28577.3f
270 schema:familyName Raikou
271 schema:givenName M.
272 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720431761.48
273 rdf:type schema:Person
274 sg:person.0734456474.38 schema:affiliation grid-institutes:grid.4991.5
275 schema:familyName Clarke
276 schema:givenName P.
277 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734456474.38
278 rdf:type schema:Person
279 grid-institutes:grid.28577.3f schema:alternateName Department of Economics, City University, London, UK, GB
280 schema:name Department of Economics, City University, London, UK, GB
281 rdf:type schema:Organization
282 grid-institutes:grid.4991.5 schema:alternateName Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB
283 Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB
284 schema:name Diabetes Trials Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, GB
285 Health Economics Research Centre, Department of Public Health, University of Oxford, Institute of Health Sciences, Headington, Oxford, UK, GB
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...